FLT3 and acute myeloid leukemia: For example, patients with acute myeloid leukemia (AML) carrying the FLT3 mutation may receive a targeted therapy like midostaurin or gilteritinib to inhibit the activity of the mutated FLT3 protein, potentially leading to improved outcomes and reduced side effects compared to traditional chemotherapy [26,27].